Effect of HIV infection status and Anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants

Journal of Infectious Diseases

Volumn 202, Issue 3, 2010, Pages 355-361

  Madhi, Shabir A ^a,b   Adrian, Peter ^a,b   Cotton, Mark F ^e   McIntyre, James A ^c,d   Jean Philippe, Patrick ^f   Meadows, Shawn ^g   Nachman, Sharon ^h   Käyhty, Helena ^j   Klugman, Keith P ^b,i   Violari, Avye ^c  

^a Vaccine Preventable Diseases ^*  (Australia)

^b Faculty of Health Science   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d ANOVA HEALTH INSTITUTE   (South Africa)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f Henry Jackson Foundation   (United States)

^g Pharmaceutical Product Development   (United States)

^h STONY BROOK UNIVERSITY   (United States)

ⁱ EMORY UNIVERSITY   (United States)

^j NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE; LOPINAVIR; PNEUMOCOCCUS VACCINE; RITONAVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BACTERIUM ANTIBODY; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; OPSONIN;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL PNEUMONIA; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONJUGATE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEWBORN; OPSONOPHAGOCYTIC ACTIVITY; PHAGOCYTOSIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; ADULT; BLOOD; IMMUNOLOGY; PREGNANCY; PREGNANCY COMPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIBODIES, BACTERIAL; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; OPSONIN PROTEINS; PHAGOCYTOSIS; PNEUMOCOCCAL VACCINES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; YOUNG ADULT;

EID: 77954709864     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/653704     Document Type: Article

References (15)

1. Nachman S, Kim S, King J et al. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 2003;112(1 Pt 1): 66-73
2. King JC Jr, Vink PE, Farley JJ, Smilie M, Parks M, Lichenstein R. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics 1997;99(4):575-580.
3. Madhi SA, Kuwanda L, Cutland C, Holm A, Kayhty H, Klugman KP. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 2005;24(5):410-416.
4. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004;364(9441):1236-1243.
5. Violari A, Cotton MF, Gibb DM et al. Early antiretroviral therapy and mortality among HIV-infected infants. NEngl JMed 2008;359(21):2233-2244.
6. Scaling up antiretroviral therapy in resource limited settings: guidelines for a public health approach. Geneva, Switzerland: World Health Organization, 2002.
7. Division of AIDS toxicity table for grading severity of pediatric (>3 months of age) adverse experiences April, 1994. http://hsc.unm.edu/ som/gcrc/ftp/ToxicityTables-Pediatric-Under3MonthsAge.pdf. Accessed 1 February 2010.
8. Romero-Steiner S, Libutti D, Pais LB, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997; 4(4):415-422.
9. Plikaytis BD, Goldblatt D, Frasch CE, et al. An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. J Clin Microbiol 2000; 38(6):2043-2050.
10. Madhi SA, Klugman KP, Kuwanda L, Cutland C, Kayhty H, Adrian P. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis 2009; 199(8):1168-1176.
11. Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007; 25(19):3816-3826.
12. Clerici M, Saresella M, Colombo F, et al. T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. Blood 2000; 96(12):3866-3871.
13. Van Rie A, Madhi SA, Heera JR, et al. Gamma interferon production in response to Mycobacterium bovis BCG and Mycobacterium tuberculosis antigens in infants born to human immunodeficiency virusinfected mothers. Clin Vaccine Immunol 2006; 13(2):246-252.
14. Mansoor N, Scriba TJ, de Kock M, et al. HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette- Guerin vaccine. J Infect Dis 2009; 199(7):982-990.
15. Dagan. R, Givon-Lavi. N, Greenberg. D, Fritzell. B, Siegrist CA. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2010; 201:1570-1579.